- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07947186
Early Feasibility Study of a Novel Male Contraceptive Device: Safety, Usability, and Acceptability Outcomes
This is a Phase 1 feasibility study evaluating the safety, barrier efficacy, and user acceptability of a novel male contraceptive device, the Galactic Cap (GC), an adhesive, polyurethane-based barrier designed to cover the glans penis. Unlike traditional condoms, the device adheres directly to the penile surface to improve fit, reduce slippage, and enhance sensation through increased skin-to-skin contact and improved heat transfer. The study will enroll 40 monogamous heterosexual couples in which the male partner has undergone vasectomy, allowing assessment of device performance independent of pregnancy risk. Participants will use the device during four separate acts of vaginal intercourse over approximately one month, with data collected via genital examinations, participant diaries, post-use surveys, and pre- and post-coital vaginal swabs analyzed for prostate-specific antigen (PSA) to assess semen leakage. The primary objective is to evaluate safety, with secondary assessment of barrier effectiveness and exploratory evaluation of device performance and user satisfaction compared to traditional condoms.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Carmel, Indiana, United States, 46032
- Recruiting
- Indiana University Men's Health Clinic Indiana University Health North Hospital
-
Contact:
- Helen Bernie, DO, MPH
- Phone Number: 317-688-5500
- Email: hbernie@iu.edu
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University Men's Health Clinic Indiana University Health North Hospital
-
Contact:
- Helen Bernie
- Phone Number: 317-688-5500
- Email: hbernie@iu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:• Heterosexual couples in monogamous stable relationships (>6 months);
- Both male and female participants are required to have >18 years old prior to entering the study;
- Eligible men are those with a prior vasectomy and documented azoospermia on semen analysis prior to the baseline visit;
- Patients must provide a signed and dated informed consent form, indicating their understanding and agreement to participate;
- Patients must be willing to comply with all study procedures and be available for the duration of the study period;
- Both male and female participants are required to have prior experience using a male condom during intercourse;
- All participants (both male and female) must be in good general health based on their medical history and physical examination. At study entry, male participants must have no open penile lesions or lacerations as confirmed by genital exam, and female participants must have no vaginal lesions or lacerations as confirmed by vaginal exam. Participants with significant genital findings at baseline will not be included in this study.
Exclusion Criteria:
-
Participants will be excluded if they do not meet any of the inclusion criteria. Exclusion criteria comprise:
- Couples who are not heterosexual or monogamous;
- Relationships lasting less than six months;
- Individuals under 18 years of age;
- Male participants who have not undergone a prior vasectomy or who do not have a semen analysis confirming azoospermia before the baseline visit;
- Inability or unwillingness to provide signed and dated informed consent;
- Inability to comply with all study procedures;
- Unavailability for the full duration of the study;
- Either partner lacking prior experience with male condom use during intercourse;
- Presence of penile or vaginal lesions or lacerations in either partner, detected during medical physical examination;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Galactic cap
Increase use of male contraception; Preventing transmission of bodily fluids |
Use galactic cap four times per week for two weeks |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Device Safety
Time Frame: Day 1 to Day 30
|
Any potential risk or adverse events associated with device use |
Day 1 to Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Barrier efficacy
Time Frame: Day 7 through day 30
|
Rate of prostate specific antigen (PSA) detection in post coital vaginal samples |
Day 7 through day 30
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 28227
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.